Paclitaxel 80, Breast Cancer, adjuvant
Protocol-ID: 581 V1.2 (Short), PACL80, Breast Ca, adj.Indication(s)
- Breast Cancer; ICD-10 C50.-
Protocol classification
- Classification: alternative
- Intensity: Standard dose
- Therapy phase:
- Therapy intention: curative
Cycles
Cycle length 7 days, recommended cycles: 12
Protocol sequences
- EC (EPIR90/CYCL600), Breast Ca, adj. (PID579) -|- PACL80, Breast Ca, adj. (PID581)
- EC (EPIR90/CYCL600), Breast Ca, adj., dd (PID2702) -|- PACL80, adj. (PID581)
- SWOG S0221: AC (DOXO60/CYCL600), Breast Ca, adj., dd, var. 1 (PID478) -|- PACL80, adj. (PID581)
- AC (DOXO60/CYCL600), Breast Ca, adj. (PID599) -|- PACL80, adj. (PID581)
Risks
- Emetogenicity (MASCC/ESMO): low (10-30%)
- Neutropenia: low (<10%) °3-4: 2%
- Febrile Neutropenia: low (<10%) °3-4: 1%
- Infections: CTC AE °3-4: 3%
- Fatigue: CTC AE °3-4: 3%
- Neuropathy: CTC AE °2-4: 27%
- Myalgias: CTC AE °3-4: 2%
Therapy
HYD Hydration: Balanced Crystalloid Solution | |||||||
| Access: peripheral venous | |||||||
| Hydration before, during, or after antitumor therapy | |||||||
| Day | Substance | Dosage | Solution | Appl. | Inf. time | Procedure | |
|---|---|---|---|---|---|---|---|
| 1 | Balanced Crystalloid Solution | 500 ml | i.v. | 30 min | 30 min before Paclitaxel (d1) | ||
AP Allergy prophylaxis: Paclitaxel Allergy Prophylaxis | |||||||
| Access: peripheral venous | |||||||
| Dexamethasone, dimetinden maleate, cimetidine | |||||||
| Day | Substance | Dosage | Solution | Appl. | Inf. time | Procedure | |
|---|---|---|---|---|---|---|---|
| 1 | Dexamethasone | 20 mg | NaCl 0.9% 50 ml | i.v. | 5 min | 30 min before Paclitaxel (d1) | |
| 1 | Dimetinden | 4 mg | NaCl 0.9% 50 ml | i.v. | 5 min | 30 min before Paclitaxel (d1) | |
| 1 | Cimetidine | 300 mg | NaCl 0.9% 50 ml | i.v. | 5 min | 30 min before Paclitaxel (d1) | |
CTX Antineoplastic therapy: Paclitaxel 80 mg/m² | |||||||
| Access: peripheral venous | |||||||
| weekly therapy | |||||||
| Day | Substance | Dosage | Solution | Appl. | Inf. time | Procedure | |
|---|---|---|---|---|---|---|---|
| 1 | Paclitaxel | 80 mg/m² BSA | NaCl 0.9% 250 ml | i.v. | 60 min | Sequence | |
Concomitant therapy supplements
Dexamethasone for antiemesis is covered by dexamethasone of allergy prophylaxis.
References
- Sparano JA, Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008 Apr 17;358(16):1663-71. doi: 10.1056/NEJMoa0707056. PMID: 18420499. [PMID]
- De Laurentiis M, Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008 Jan 01;26(1):44-53. doi: 10.1200/JCO.2007.11.3787. PMID: 18165639. [PMID]
- Budd GT, SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 2015 Jan 01;33(1):58-64. doi: 10.1200/JCO.2014.56.3296. PMID: 25422488. [PMID]
- Shulman LN, Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 2014 Aug 01;32(22):2311-7. doi: 10.1200/JCO.2013.53.7142. PMID: 24934787. [PMID]
Links
- One-hour paclitaxel infusions: review of safety and efficacy. [PMID]
Recommendations
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 16.09.2023